240 related articles for article (PubMed ID: 12087448)
1. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
Twelves CJ; Cassidy J
Br J Cancer; 2002 Jun; 86(11):1670-6. PubMed ID: 12087448
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
3. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
4. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
6. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Twelves C; Gollins S; Grieve R; Samuel L
Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Iqbal S; Lenz HJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
[TBL] [Abstract][Full Text] [Related]
8. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
9. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Ward SE; Kaltenthaler E; Cowan J; Marples M; Orr B; Seymour MT
Br J Cancer; 2006 Jul; 95(1):27-34. PubMed ID: 16804526
[TBL] [Abstract][Full Text] [Related]
10. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Van Cutsem E; Hoff PM; Harper P; Bukowski RM; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun JA; Marshall JL; Mitchell EP; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky RL
Br J Cancer; 2004 Mar; 90(6):1190-7. PubMed ID: 15026800
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
McGavin JK; Goa KL
Drugs; 2001; 61(15):2309-26. PubMed ID: 11772141
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
Twelves C;
Eur J Cancer; 2002 Feb; 38 Suppl 2():15-20. PubMed ID: 11841931
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
[TBL] [Abstract][Full Text] [Related]
15. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Cunningham D; James RD
Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer: chemotherapy treatment overview.
Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
[TBL] [Abstract][Full Text] [Related]
17. [Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Croockewit AJ; de Boer JE; van Loenhout JW; Koopmans PP
Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1117-20. PubMed ID: 12092301
[TBL] [Abstract][Full Text] [Related]
18. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
19. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky RL;
Ann Oncol; 2002 Apr; 13(4):566-75. PubMed ID: 12056707
[TBL] [Abstract][Full Text] [Related]
20. Answering patients' needs: oral alternatives to intravenous therapy.
Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
